LAPSCOVERYTM
Long Acting Protein / Peptide Discovery Platform Technology
Overview
Biologics have a short half-life when administered to the human body. This results in the need for frequent injections and inconvenience to patients. LAPSCOVERYTM (Long Acting Protein/Peptide Discovery) is a platform technology that prolongs the active duration of biologics and makes it possible for once-weekly or monthly drug administration.
Therapeutic Moiety
Any modalities applicable: Protein (glycosylated, non-glycosylated), Peptide (natural/unnatural)
Flexible Linker
Reduce Immunogenicity Minimized loss of activity No loss of FcRn binding
Aglycosylated Fc
FcRn mediated endothelium recycling Increased solubility
-
Longer Duration
- Monomeric form helps to reduce receptor mediated clearance
- FcRn mediated endothelium recycling / Avoiding renal filtration
-
Efficacy ↑ Side Effects↓
- Flexible linker minimizes loss of intrinsic activity
- Monomeric form helps to reduce RMC
- Highest bioavailability reduces dose level